@article{3a73687089cc486684c4665177fb8459,
title = "Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients",
abstract = "Background: Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission. Methods: This observational study included 453 severe asthma patients (41% male; mean age ± SD 55.7 ± 14.7 years) from two real-world drug registries: the Australian Mepolizumab Registry and the Australian Xolair Registry. The composite outcome clinical remission was defined as zero exacerbations and zero oral corticosteroids during the previous 6 months assessed at 12 months and 5-item Asthma Control Questionnaire (ACQ-5) ≤1 at 12 months. We also assessed clinical remission plus optimization (post-bronchodilator FEV1 ≥80%) or stabilization (post-bronchodilator FEV1 not greater than 5% decline from baseline) of lung function at 12 months. Sensitivity analyses explored various cut-offs of ACQ-5/FEV1 scores. The predictors of clinical remission were identified. Results: 29.3% (73/249) of AMR and 22.8% (37/162) of AXR cohort met the criteria for clinical remission. When lung function criteria were added, the remission rates were reduced to 25.2% and 19.1%, respectively. Sensitivity analyses identified that the remission rate ranged between 18.1% and 34.9% in the AMR cohort and 10.6% and 27.2% in the AXR cohort. Better lung function, lower body mass index, mild disease and absence of comorbidities such as obesity, depression and osteoporosis predicted the odds of achieving clinical remission. Conclusion: Biologic treatment with mepolizumab or omalizumab for severe asthma-induced asthma remission in a subgroup of patients. Remission on treatment may be an achievable treatment target and future studies should consider remission as an outcome measure.",
keywords = "asthma, mepolizumab, omalizumab, remission",
author = "Dennis Thomas and McDonald, {Vanessa M.} and Sean Stevens and Harvey, {Erin S.} and Melissa Baraket and Philip Bardin and Bowden, {Jeffrey J.} and Simon Bowler and Jimmy Chien and Chung, {Li Ping} and Andrew Gillman and Mark Hew and Sandra Hodge and Alan James and Christine Jenkins and Katelaris, {Constance H.} and Katsoulotos, {Gregory P.} and David Langton and Joy Lee and Guy Marks and Matthew Peters and Naghmeh Radhakrishna and Reynolds, {Paul N.} and Janet Rimmer and Pathmanathan Sivakumaran and Upham, {John W.} and Peter Wark and Yang, {Ian A.} and Gibson, {Peter G.}",
note = "Funding Information: D. Thomas reports grants from GlaxoSmithKline, outside the submitted work. V.M. McDonald reports grants and personal fees from GlaxoSmithKline, AstraZeneca and Menarini, outside the submitted work. S. Stevens has nothing to disclose. E.S. Harvey reports grants from GlaxoSmithKline that were paid to her employer, during the conduct of the study. M. Baraket has nothing to disclose. P. Bardin reports per patient trial participation fees from Monash Lung and Sleep, during the conduct of the study; personal fees for advisory board work, outside the submitted work. J. Bowden reports personal fees for advisory board work from GlaxoSmithKline, AstraZeneca and Novartis, outside the submitted work. S. Bowler reports personal fees for advisory board work from GlaxoSmithKline, outside the submitted work. J. Chien reports personal fees from GlaxoSmithKline, outside the submitted work. L.P. Chung reports honorariums for educational activities and /or consultation fees from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Boehringer Ingelhein and Menarini, outside the submitted work. A. Gillman reports personal fees for advisory board work and education from GlaxoSmithKline, outside the submitted work. M. Hew reports grants and personal fees from AstraZeneca, GlaxoSmithKline and Novartis, personal fees from Sanofi, Teva and Seqirus, outside the submitted work; all paid to his institutional employer Alfred Health. S. Hodge has nothing to disclose. A. James has nothing to disclose. C. Jenkins reports personal fees for advisory board work, conducting meetings and developing educational content, and non‐financial support from AstraZeneca, personal fees for advisory board work from Boehringer Ingleheim, grants and personal fees for advisory board work from GlaxoSmithKline, personal fees for advisory board work, facilitating symposia and developing educational content from Novartis, outside the submitted work. C. Katelaris reports grants from GlaxoSmithKline, during the conduct of the study; grants and personal fees for advisory board work and lectures from Sanofi, Novartis and CSL, personal fees from Seqirus and Takeda, outside the submitted work. G.P. Katsoulotos has nothing to disclose. D. Langton has received fees from GlaxoSmithKline for participation in severe asthma advisory boards. J. Lee has received fees for providing unrelated independent medical advice for GlaxoSmithKline and has received speaker fees for medical education purposes from Boehringer Ingelheim, GlaxoSmithKline and AstraZeneca. G. Marks has nothing to disclose. M. Peters reports personal fees for advisory board work from Sanofi Genzyme, Novartis Pharmaceuticals and AstraZeneca, outside the submitted work. N. Radhakrishna reports grants from Sanofi and speaker fees from GSK, AstraZeneca, Mundipharma, Sanofi and Mylan. P.N. Reynolds has nothing to disclose. J. Rimmer reports speaker/sponsorship fees from GSK, Stallergenes and Sanofi. P. Sivakumaran has nothing to disclose. J. W. Upham has received speaker fees, conference travel support and consultancy fees from AstraZeneca, GSK, Novartis, Boehringer Ingelheim and Sanofi. P. Wark reports grant from GlaxoSmithKline. I.A. Yang has nothing to disclose. Gibson reports grants from GlaxoSmithKline, during the conduct of the study; personal fees for lectures from AstraZeneca, GlaxoSmithKline and Novartis, grants from AstraZeneca and GlaxoSmithKline, outside the submitted work. Funding Information: We thank the physicians, staff, and patients at the clinical sites for supporting the registries. Open access publishing facilitated by The University of Newcastle, as part of the Wiley - The University of Newcastle agreement via the Council of Australian University Librarians. Publisher Copyright: {\textcopyright} 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",
year = "2024",
month = feb,
doi = "10.1111/all.15867",
language = "English",
volume = "79",
pages = "384--392",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "2",
}
